Renewing interest in targeting angiogenesis in glioblastoma
Mené aux Pays-Bas sur 153 patients atteints d'un glioblastome récidivant, cet essai de phase II évalue l'efficacité, du point de vue de la survie globale à 9 mois, et la toxicité du bevacizumab, seul ou en combinaison avec la lomustine
Angiogenesis is a hallmark of glioblastoma and is one of the features used frequently by pathologists to make this histological diagnosis and to assess tumour grade. Extensive studies have been undertaken into the biology of the neovascularisation that is an integral component of the highly malignant phenotype of glioblastoma. Characteristically, these rapidly formed blood vessels are tortuous, leaky, and often have blind loops, resulting in inefficient blood flow and account for much of the per ...
The Lancet Oncology , commentaire, 2013